<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397826</url>
  </required_header>
  <id_info>
    <org_study_id>0733-265</org_study_id>
    <nct_id>NCT00397826</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Simvastatin 40mg</brief_title>
  <official_title>Evaluation of the Effects of Simvastatin 40 Mg on Lipid Profiles and Specified Circulatory Parameters in Normotensive Hypercholesterolemia Patients(MK-0733-265)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardinal Tien Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardinal Tien Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect lipid-lowering response data with the use of simvastatin 40 mg tablet in patients
      with hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, prospective study to investigate lipid-lowering efficacy and
      sympathetic response of normotensive hypercholesterolemia patients after receiving
      simvastatin 40 mg once daily for 3 months.

      The total duration of the study will be approximately 13 weeks, comprising of a 1-week (or 4
      weeks?) screening period and a 12-week active treatment period. 20 hypercholesterolemia
      patients with normal blood pressure will be enrolled into treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total cholesterol, ldl-c, hdl-c, and triglycerides</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baroreflex sensitivity</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum nitrite, nitrate and urine c-gmp levels after 12 weeks treatment</measure>
    <time_frame>after 12 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>MK0733,simvastatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>20 patients with total cholesterol ≧ 240 mg/dL or LDL-C &gt; 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0733</intervention_name>
    <description>Duration of Treatment: 12 Weeks</description>
    <arm_group_label>MK0733,simvastatin</arm_group_label>
    <other_name>simvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient, &gt;18 years of age

          -  Patients with hypercholesterolemia who meet the following lipid criteria:

               1. primary cholesterolemia: total cholesterol&gt;=240 mg/dl or ldl-c &gt;= 160 mg/dl

               2. secondary cholesterolemia (patients with cad, dm): ldl-c&gt;=130 mg/dl

          -  The patient is willing to follow an NCEP therapeutic lifestyle changes (tlc) or
             similar cholesterol-lowering diet throughout the duration of the study

        Exclusion Criteria:

          -  Congestive heart failure (NYHA class III or IV), uncontrolled cardiac arrhythmia,
             unstable angina

          -  Hypertension (based on the atp 3 guidelines)

          -  Taking potent lipid-lowering agents

          -  Unstable diabetes (hba1c &gt;9%) or newly diagnosed (within 3 months), or a change in
             anti-diabetes medications within 3 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Feng Yeih, MD,Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardinal Tiem Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardinal Tien Hospital</investigator_affiliation>
    <investigator_full_name>Dong Feng Yeih</investigator_full_name>
    <investigator_title>Attending Physician of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

